Neurologix Announces Q3 Results
14th Nov 2006, 14:39 GMT
Neurologix, a biotech company engaged in the development of innovative gene therapies for the brain and central nervous system, announced its financial results for the quarter and 9 months ended 9/30/2006.
Neurologix Announces Q3 Results related news:
- Orion HealthCorp Announces Q3 Results — StratWire - Business of Healthcare NewsFeed
- Chembio Diagnostics Announces Q3 Results — Operations-Related News from StratCenter.com
- j2 Global Announces Anticipated Timing of Release of Q3 2006 Results and Related Earnings Call and Filings of Q2 and Q3 2006 Quarterly Reports of Form 10-Q — VoIP Developer
- Webcast Alert: InSite Vision Announces Its Q3 FYE 2006 Financial Results Webcast — Partnerships/ Joint Ventures News from StratCenter.com
- Human Pheromone Sciences Announces Q3 Results — StratWire - Business of Healthcare NewsFeed
- MQ Assoc Announces Results for Q3 of 2006 and 9 Months Ended 9/30/2006 — Executive Announcements News from StratCenter.com
- Chemokine Therapeutics announces Q3 2006 financial and operating results — Bio-Technology News from StratCenter.com
- Viscount Systems Inc.: Viscount Reports Q3 2006 Results — Market Wire - Telecom
- Stratagene Reports Q3 Results — Laboratory News from StratCenter.com
- eGene Reports a Profitable Quarter Result and Revenue Increases 273% in Q3 2006 Compared to Q3 2005 — Operations-Related News from StratCenter.com
Latest news from Neurology News from StratCenter.com:
- Alzheimer's Foundation of America to Hold Nat'l Memory Screening Day
- Kensey Nash Announces Commencement of Carotid Pivotal Trial for TriActiv ProGuard System
- New Study Finds Everyday Activities Trigger Smoking Cravings
- Neurobiological Technologies Review Issued by Scimitar Equity Research
- AQA Adopts Additional Standard Quality Measures for Practitioners in 25 Surgical and Medical Specialties
- StemCells' product transplanted in early clinical trial
- Acorda Therapeutics Added to NASDAQ Biotech Index
- StemCells Begins Study on Rare Disease
- StemCells Announces 1st Human Neural Stem Cell Transplant
- Vanda Pharmaceuticals' VEC-162 Demonstrates Positive Results in a Phase III Transient Insomnia Clinical Trial